HSP90 as a novel molecular target in non-small-cell lung cancer

Khashayar Esfahani
Victor Cohen
Segal Cancer Center, Jewish General Hospital, McGill University, Montreal, QC, Canada

Correspondence: Victor Cohen
Segal Cancer Center, Jewish General Hospital, 3755 Chemin de la Côte-Sainte-Catherine, Montreal, QC, H3T 1E2, Canada
Email vcohen@jgh.mcgill.ca

Abstract: Lung cancer remains the most lethal cancer, with over 160,000 annual deaths in the USA alone. Over the past decade, the discovery of driver mutations has changed the landscape for the treatment of non-small-cell lung cancer (NSCLC). Targeted therapies against epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) have now been approved by the US Food and Drug Administration as part of the standard first-line treatment of NSCLC. Despite good initial responses, most patients develop resistance within 8–12 months and have disease progression.

Keywords: non-small-cell lung cancer, driver mutations, targeted therapy, heat shock protein 90 (HSP90)

Introduction
Lung cancer remains the most lethal cancer, with over 160,000 annual deaths in the USA alone.1 Over the past decade, the discovery of driver mutations has changed the landscape for the treatment of non-small-cell lung cancer (NSCLC).2 Targeted therapies against epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) have now been approved by the US Food and Drug Administration as part of the standard first-line treatment of NSCLC. Despite good initial responses, most patients develop resistance within 8–12 months and have disease progression.

HSP90 is a chaperone protein assisting other cellular proteins to fold properly, and stabilizes them against oxidative and heat stress, as well as helping with protein degradation.3 HSP90 is a weak ATPase with a very rapid turnover rate (0.1/minute in humans). Unlike ALK and EGFR NSCLC that is driven by oncogenic mutations, the activity of HSP90 is regulated by the binding of cochaperone molecules that induce conformational change in the HSP90. To date, over 20 cochaperone molecules have been identified.3

Recent insights from the Cancer Genome Atlas revealed that multiple malignancies overexpress or possess mutant kinases that depend on the HSP90–chaperone complex.3 HSP90 has been shown to stabilize various signaling molecules, such as PI3K and AKT proteins, thus inhibiting cellular apoptosis in cancerous cells (Figure 1).4 It also appears that HSP90 can act as a “protector” of unstable protein by-products of DNA mutations, such as v-SRC and mutant forms of p53.5 Relevant to NSCLC, mutant EGFR,6 ERBB2,7 MET,8 mutant BRAF,9 and the EML4–ALK translocation product10 are all HSP90-dependent proteins, the degradation of which leads to loss of tumor-cell viability in the corresponding adenocarcinoma subset. Expression of HSP90 has thus
been shown to correlate with a worse clinical prognosis and to be correlated with resistance to chemo- and radiotherapy.13

The first class of HSP90 inhibitors to be characterized were the benzoquinone ansamycins, including geldanamycin and its derivatives 17-allylamino-17-demethoxygeldanamycin (17-AAG) and 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG).14 They were derivatives of geldanamycin, which is an ansamycin antibiotic derived from a Streptomyces sp., and block ATP binding to the active site of HSP90. However, the clinical application of these drugs was limited by their poor pharmacokinetics and dynamics, including poor solubility, formulation problems, and potential multidrug efflux.15 As single agents, these molecules have shown only limited efficacy, thus pointing toward better results in combination therapy.16 In an effort to overcome these limitations, several second-generation synthetic HSP90 inhibitors representing multiple drug classes are currently under development.

The goal of this review is to present the data supporting the use of HSP90 inhibitors in NSCLC and to give an overview of the ongoing clinical trials involving new-generation HSP90 inhibitors. The summary of selected trials involving HSP90 inhibitors is presented in Table 1.

**Ganetespib (STA-9090)**

Ganetespib, also known as STA-9090, is a resorcinol derivative that binds the ATP-binding pocket of HSP90 and leads to its inhibition. Ganetespib acts by inducing G2/M cell-cycle phase arrest, resulting in apoptosis within 48 hours of treatment. It has also been shown to induce cell arrest in both erlotinib-sensitive and erlotinib-resistant cell lines, including H1975 with the T790M gatekeeper mutation.17 Compared to the older generation 17-AAG, ganetespib has greater potency and potential efficacy against several NSCLC subsets, including those harboring EGFR or ERBB2 mutations.18 Treatment with ganetespib resulted in decreased downstream signaling through the PI3K–AKT–mTOR and RAF–MEK–ERK pathways.

In ALK-rearranged NSCLC cell lines, ganetespib induced loss of EML4–ALK expression and depletion of multiple oncogenic signaling proteins in ALK-driven NSCLC cells, leading to greater in vitro potency, superior antitumor efficacy, and prolonged animal survival compared with crizotinib monotherapy.19,20 Ganetespib also overcame multiple forms of crizotinib resistance, including secondary ALK mutations. Cancer cells driven by ALK amplification and oncogenic rearrangements of the ROS1 and RET kinase genes were also sensitive to ganetespib exposure.

HSP90 inhibition with ganetespib has also resulted in decreased viability of KRAS-mutated cell lines by impacting downstream signaling through the mTOR and MEK pathways.21 It was superior to both AZD6244, an MEK inhibitor, and BEZ235, a PI3K/mTOR inhibitor when used as monotherapy, and also helped sensitize KRAS-mutated cell lines to cisplatin, pemetrexed, gemcitabine, and docetaxel.
HSP90 inhibitors have been shown to exert synergistic activity when combined with taxanes (paclitaxel and docetaxel), another G$_2$/M cell-cycle arrest inhibitor. This combination has resulted in synergistic toxicity in both cell lines and animal xenograft models, resulting in more tumor regression than with taxanes alone.22

In the first published multicenter Phase II trial, ganetespib as monotherapy was assessed in previously treated patients with NSCLC with specific genotypic subtypes.21 A total of 99 patients were enrolled in three cohorts: cohort A (n=15, mutant EGFR), B (n=17, mutant KRAS), and C (n=66, no EGFR or KRAS mutations). Patients were treated with 200 mg/m$^2$ ganetespib by intravenous infusion once-weekly for 3 weeks followed by 1 week of rest until disease progression. The primary end point of progression-free survival (PFS) at 16 weeks was achieved in 13.3% of EGFR-mutated patients, 5.9% of KRAS-mutated patients, and 19.7% of wild-type patients; 4% of patients achieved partial response, all harboring the ALK translocation. Eight (8.1%) patients experienced treatment-related serious adverse events, two of which (cardiac arrest and renal failure) resulted in death. The most common other adverse effects were diarrhea, fatigue, nausea, and anorexia.

Given early success in preclinical studies as combination therapy with taxanes, ganetespib was assessed in a Phase I trial in combination with docetaxel. The study, with 27 patients, defined the maximum tolerated dose (MTD) of ganetespib at 150 mg/m$^2$ on days 1 and 15 of each 21-day cycle.24 The dose-limiting toxicities were febrile neutropenia and grade 4 neutropenia. Other adverse effects included anemia, fatigue, nausea, and diarrhea. This combination was further assessed in the Phase II GALAXY-I trial comparing docetaxel to docetaxel plus ganetespib;2526 225 patients with advanced NSCLC, one prior systemic therapy, and Eastern Cooperative Oncology Group performance status of 0/1 were included. Docetaxel was given at 75 mg/m$^2$ on day 1 of a 3-week cycle. In the experimental arm, docetaxel was given on day 1 and ganetespib at 150 mg/m$^2$ on days 1 and 15. Patients were stratified by performance status, time since advanced disease diagnosis (≥6 months vs >6 months), baseline lactate dehydrogenase (LDH) (elevated or normal), or smoking status. The rationale for including patients with elevated LDH was the correlation with tumor hypoxia in these patients attributable to HIF-1α, a client protein of HSP90. After 72 patients were enrolled, nonadenocarcinoma patients were excluded, given the lack of efficacy and excess bleeding risk. For the combination vs the monotherapy arm, the median number of cycles delivered was five vs four, and grade 3/4 adverse events were neutropenia 38% vs 37%, fatigue 4% vs 3%, anemia 7% vs 6%, diarrhea 3% vs 0%, and fever with neutropenia 8% vs 2%. In this study, the overall survival hazard ratio (HR) was 0.69 (95% confidence interval [CI] 0.48–0.99, P=0.093), the PFS HR was 0.70 (95% CI 0.53–0.94, P=0.012), and the overall response rate (ORR) was 15% vs 11%, all favoring the combination arm. For patients that were enrolled >6 months after diagnosis of advanced NSCLC (n=175, 69%), a prespecified stratification factor, the overall survival HR was 0.41 (95% CI 0.25–0.67, P=0.0009), the PFS HR was 0.47 (95% CI 0.32–0.69, P=0.0005), and the ORR was 16% vs 12%.

### Table 1  Key completed trials involving HSP90 inhibitors

<table>
<thead>
<tr>
<th>Drug name</th>
<th>Trial information</th>
<th>Stratification</th>
<th>End point</th>
<th>ORR</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ganetespib</td>
<td>NCT01031225 n=99</td>
<td>Cohort A: mutant RAS</td>
<td>PFS at 16 weeks</td>
<td>4% (only seen in patients with ALK translocation)</td>
<td>Two deaths (one cardiac arrest and one renal failure)</td>
</tr>
<tr>
<td></td>
<td>Phase II</td>
<td>Cohort B: mutant EGFR</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Cohort C: wild type</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GALAXY-I</td>
<td>NCT01348126 n=255</td>
<td>LDH</td>
<td>OS: HR 0.69</td>
<td>15% in the combination arm</td>
<td>Best response achieved in patients with &gt;6 months since advanced diagnosis (HR 0.41)</td>
</tr>
<tr>
<td></td>
<td>Phase II</td>
<td>RAS mutation</td>
<td>PFS: HR 0.70</td>
<td>11% in stand-alone arm</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Time since advanced disease</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Performance status</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Combination drug: docetaxel</td>
<td>Smoking</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AUY922</td>
<td>NCT01922583 n=112</td>
<td>EGFR-mutated</td>
<td>ORR and SD at 18 weeks</td>
<td>EGFR: 18%</td>
<td>SD achieved in some crizotinib-resistant patients</td>
</tr>
<tr>
<td></td>
<td>Phase II</td>
<td>KRAS-mutated</td>
<td>Overall: 13%</td>
<td>KRAS: 0%</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>ALK-rearranged</td>
<td></td>
<td>ALK: 25%</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Wild type</td>
<td></td>
<td>Wild type: 13%</td>
<td></td>
</tr>
<tr>
<td>Retaspimycin (iPi-504)</td>
<td>NCT00431015 n=76</td>
<td>EGFR wild-type</td>
<td>ORR of 7%</td>
<td>EGFR wild-type: 10%</td>
<td>Grade 3 liver dysfunction in 11% of patients</td>
</tr>
<tr>
<td></td>
<td>Phase II</td>
<td>EGFR-mutated</td>
<td></td>
<td>EGFR-mutated: 4%</td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: ORR, overall response rate; PFS, progression-free survival; OS, overall survival; HR, hazard ratio; SD, stable disease; EGFR, epidermal growth factor receptor; ALK, anaplastic lymphoma kinase; LDH, lactate dehydrogenase.
Given positive results from this study, multiple Phase III trials are under way to assess the efficacy of ganetespib in other adenocarcinomas, including breast cancer.

**AUY922**

AUY922 is a second-generation nongeldanamycin HSP90 inhibitor that is an isoxazole derivative. In preclinical studies, it has been shown to have clinical activity in lung cancer cells with MET- and AXL-mediated resistance. 27 AUY922 treatment effectively suppressed proliferation and induced cell death in both resistant cell lines by downregulating EGFR, MET, and AXL expression, which led to decreased AKT-pathway activation. AUY922 has also been shown to act as a radiosensitizer to cell lines with acquired resistance to EGFR inhibitors. 28–30 These cell-line studies have been replicated in animals with NSCLC xenograft tumors with MET- and AXL-mediated resistance. 27

A total of 101 patients were enrolled in the first-in-human dose-escalation study of AUY922 in patients with solid tumors. 31 The MTD was not reached; however, because of concerns regarding visual toxicity, dose escalation beyond 70 mg/m² was not attempted. Dose-limiting toxicities occurred in eight patients, and included diarrhea, asthenia/fatigue, anorexia, atrial flutter, and visual symptoms. At 70 mg/m², the AUY922 concentration achieved was consistent with active concentrations in a range of xenograft models, and that dose was recommended to be taken forward in Phase IB and Phase II studies. All 101 patients were evaluable for a clinical response, and of these, none had a complete or partial response by adapted Response Evaluation Criteria in Solid Tumors criteria.

The first Phase II trial evaluated AUY922 in 112 patients with NSCLC, 61% of which had received at least three lines of therapy. 32 Patients were stratified in to four groups: EGFR-mutated, KRAS-mutated, ALK-rearranged, and wild-type NSCLC. Mean duration of exposure was 9 weeks. In a preliminary report presented at the American Society of Clinical Oncology 2012 conference, partial responses were seen in 13 out of 101 (13%) patients, two out of eight (25%) ALK-rearranged patients, six out of 33 (18%) EGFR-mutated patients, four out of 30 (13%) wild-type patients, zero out of 26 (0%) KRAS-mutated patients, and one out of four (25%) patients of unknown status. In ALK-rearranged patients, responses were seen in crizotinib-naïve patients, and stable disease was seen with tumor shrinkage in crizotinib-resistant patients. The most frequent adverse events were diarrhea (73%), visual disturbances (71%), and nausea (43%).

These data were updated at the 2013 American Society of Clinical Oncology Annual Meeting, with a focus on EGFR-mutated patients. Data for 16 patients with acquired EGFR tyrosine-kinase inhibitor (TKI) resistance were presented, seven having tested positive for EGFR T790M at rebiopsy. The ORR was two out of 16 (13%), and both patients with partial responses had the gatekeeper mutation.

Another Phase II trial looked at using AUY922 in patients with acquired resistance to erlotinib; 33 25 patients were evaluated, and the median time to TKI resistance was 11 months. Ten (40%) patients had EGFR T790M identified by tumor rebiopsy. The ORR was four out of 25 (16%). Three out of four patients with partial response had EGFR T790M mutation. An additional four patients had stable disease for at least 8 weeks. Adverse events reported in ≥20% of patients were diarrhea, fatigue, myalgia, nausea, mucositis, and night blindness; 68% (17 out of 25) experienced night blindness (grade 1–2 only), and three patients came off the study due to eye-related toxicity.

AUY922 has also been combined with trastuzumab in patients with HER2-amplified or HER2-mutated NSCLC; 34 55 patients with HER2 amplification, 34 patients with HER2 overexpression, and seven patients with HER2 mutation were treated. Final results from this study are pending publication.

**Retaspimycin (IPI-504)**

Retaspimycin or IPI-504 is a water-soluble derivative of 17-AAG that causes less liver toxicity and has shown activity in NSCLC. In preclinical studies, great responses have been obtained with retaspimycin, especially in ALK-rearranged cell lines. Treatment of H3122 ALK-rearranged cell lines with retaspimycin resulted in degradation of the fusion protein in <3 hours, making it a much more sensitive target than EGFR or HER2. 12

The first multicenter Phase II study of retaspimycin enrolled 76 patients with EGFR-mutated lung cancer that had progressed on TKI therapy. 35 The ORR was a disappointing five out of 76 (7%) in the overall study population, 10% in patients with EGFR wild-type, and 4% in patient with EGFR mutations, with a median PFS of 2.86 months. However, among three patients with ALK rearrangements, two had partial responses and had prolonged stable disease of over 7 months’ duration. Grade 3 hepatitis was observed in 12% of patients. The most common adverse effects were fatigue, nausea, and diarrhea.

Retaspimycin has also been evaluated in combination with taxanes in patients with metastatic NSCLC in an expansion of
a Phase IB trial,\textsuperscript{36} 23 patients with pathologically confirmed metastatic NSCLC, all having received one to two prior chemotherapy regimens without prior docetaxel, were enrolled. Docetaxel 75 mg/m\textsuperscript{2} IV was given once every 3 weeks, while retaspimycin 300 mg/m\textsuperscript{2} was administered intravenously once per week. Six out of the 23 (26\%) patients had a partial response, including three of seven patients with squamous cell carcinoma. The most common reported adverse effects were fatigue, diarrhea, neutropenia, and anemia.

**AT13387**

AT13387 is a potent second-generation nonansamycin HSP90 inhibitor. It has been shown to have effect in NSCLC cell lines, as well as mouse xenograft models.\textsuperscript{37} Its long duration of action has enabled once-weekly dosing.\textsuperscript{38} AT13387 has also shown clinical efficacy in ALK-rearranged cell lines, as well as mouse xenograft models injected with those cells.\textsuperscript{39}

In the first-in-human Phase I dose-escalation study, AT13387 was evaluated in 62 patients with advanced solid tumors. The drug was administered in both a twice-weekly and once-weekly regimen. One dose-limiting visual disturbance occurred at 120 mg/m\textsuperscript{2} twice weekly, thus establishing the MTD for this regimen. For the once-weekly regimen, no formal dose-limiting toxicity occurred; however, multiple moderately severe toxicities, including diarrhea, nausea, vomiting, fatigue, and systemic infusion reactions, led to selection of 260 mg/m\textsuperscript{2} as the recommended Phase II dose. The drug was administered for 3 weeks on a 4-week cycle.

**Conclusion**

The HSP90 inhibitors are a diverse group of molecules with a wide range of activity in solid tumors, with ongoing trials presented in Table 2. These compounds have demonstrated significant potential in NSCLC in both preclinical and human trials. They can also act as chemo- and radiosensitizers, as well as help circumvent acquired resistance to standard targeted therapies. The advantage of using HSP90 inhibitors is their ability to target multiple oncogenes at the same time. The GALAXY-2 study (NCT01798485), the first Phase III trial of HSP90 inhibitors in NSCLC, is ongoing. A previous study reported single amino acid mutations in the HSP90 molecule associated with in vivo resistance to HSP90 inhibitors.\textsuperscript{40} Further studies are required to identify additional predictive biomarkers of sensitivity and resistance to HSP90 inhibitors in humans.

**Disclosure**

The authors report no conflicts of interest in this work.

**References**


